GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (FRA:OXOA) » Definitions » Total Payout Ratio

Oxford BioMedica (FRA:OXOA) Total Payout Ratio : 0.37 (As of May. 10, 2025)


View and export this data going back to . Start your Free Trial

What is Oxford BioMedica Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Oxford BioMedica's current Total Payout Ratio is 0.37.


Oxford BioMedica Total Payout Ratio Historical Data

The historical data trend for Oxford BioMedica's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Total Payout Ratio Chart

Oxford BioMedica Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.25 -2.60 1.74 - 0.37

Oxford BioMedica Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - 0.48 0.05

Competitive Comparison of Oxford BioMedica's Total Payout Ratio

For the Biotechnology subindustry, Oxford BioMedica's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Total Payout Ratio falls into.


;
;

Oxford BioMedica Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Oxford BioMedica's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 21.16 + 0) / -57.065
=0.37

Oxford BioMedica's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.644 + 0) / -13.919
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.

Oxford BioMedica Headlines

No Headlines